Long-acting statin for aneurysmal subarachnoid hemorrhage: A randomized, double-blind, placebo-controlled trial. Issue 7 (July 2018)

• Record Type: Journal Article
• Authors: Naraoka, Masato; Matsuda, Naoya; Shimamura, Norihito; Asano, Kenichiro; Akasaka, Kenichi; Takemura, Atsuhito; Hasegawa, Seiko; Ohkuma, Hiroki
• Is Part Of: Journal of cerebral blood flow & metabolism. Volume 38:Issue 7(2018)
• Page Start: 1190
• Page End: 1198
• Publication Date: 2018-07
• Subjects: Subarachnoid hemorrhage -- vasospasm -- angiography -- clinical trials -- randomized controlled trials; Cerebral circulation -- Periodicals; Brain -- Metabolism -- Periodicals; Brain -- Blood-vessels -- Periodicals; Cerebrovascular disease -- Periodicals; 612.824
• DOI: 10.1177/0271678X17724682
• Languages: English
• ISSNs: 0271-678X

Abstract

Statins have pleiotropic effects that are considered beneficial in preventing cerebral vasospasm and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage (aSAH). Many studies using statins have been performed but failed to show remarkable effects. We hypothesized that a long-acting statin would be more effective, due to a longer half-life and stronger pleiotropic effects. Patients with aSAH were randomly assigned to a pitavastatin group (4 mg daily; n = 54) and a placebo group ( n = 54) after repair of a ruptured aneurysm. The primary efficacy end point was vasospasm-related delayed ischemic neurological deficits (DIND), and the secondary end points were cerebral vasospasm evaluated by digital subtraction angiography (DSA), vasospasm-related new cerebral infarctions, and outcome at three months. Severe cerebral vasospasms on DSA were statistically fewer in the pitavastatin group than in the placebo group (14.8% vs. 33.3%; odds ratio, 0.32; 95% confidence interval, 0.11–0.87, p = 0.042); however, the occurrence of DIND and new infarctions and outcome showed no statistically significant differences between the groups. The present study is the first to prove the definite, statin-induced amelioration of cerebral vasospasm on DSA. However, administration of any type of statin at the acute phase of aSAH is not recommended.